Synthetic Biology: what are the top startups?

Which AI-biology startups are actually pulling ahead?

Profluent and Latent Labs are the two names that stand out most today. Cradle, EvolutionaryScale, and Basecamp Research still matter, but they do not all have the same kind of proof.

Profluent looks like the best-funded emerging AI-biology startup right now. In November 2025, it raised $106 million, bringing total funding to about $150 million. That alone would not be enough. What makes Profluent more interesting than a generic “AI for biology” company is that its work is already tied to genome editors, antibodies, enzymes, diagnostics, agriculture, and biomanufacturing. Its OpenCRISPR-1 editor has also been used by thousands of commercial and academic users, which gives it a usage signal most AI-biology startups still do not have.

Latent Labs is the more exciting technical challenger. It came out of stealth in February 2025 with $50 million, founded by Simon Kohl from DeepMind’s AlphaFold2 team. But the real reason it has moved up the watchlist is not the DeepMind résumé. In July 2025, Latent-X reported wet-lab protein binder results using only 30 to 100 designs per target, with more than 90% experimental hit rates on macrocyclic peptide benchmarks and low-nanomolar to picomolar binding in some mini-binder work. In March 2026, Latent-Y pushed the story further with an autonomous antibody-design agent. That is a much sharper signal than “we have a foundation model.”

Cradle is probably the most practical of the group for near-term protein engineering teams. Its $73 million Series B, announced in late 2024, brought total funding above $100 million, and the company is built around helping scientists generate protein candidates without building their own AI stack. Compared with Latent Labs, the story is less technically explosive. Compared with EvolutionaryScale, it feels closer to everyday customer workflow.

EvolutionaryScale still belongs in the leader group, but the heat has cooled a bit because its biggest public signal is older. The company raised a $142 million seed round and launched ESM3, trained on 2.78 billion proteins. That was a massive technical statement. Today, though, we have fresher proof from Profluent and Latent Labs, so EvolutionaryScale remains a foundational AI-biology name rather than the hottest new mover.

Basecamp Research is the differentiated data bet. The angle they chose is that biodiversity data can become a proprietary advantage for training biology models. That is a good thesis, but compared with Profluent and Latent Labs, the public evidence is still more “strategic asset” than repeatable product proof.

So if we rank the category today, Profluent is ahead on funding plus usage, Latent Labs is ahead on fresh technical validation, Cradle is strongest on practical workflow adoption, EvolutionaryScale still has the most famous model moment, and Basecamp is the long-term data wildcard.

If you want more recent data on this point, please see our latest synthetic biology market report.

Which biomanufacturing startups are fixing the scale-up mess?

Culture Biosciences and Pow.Bio are the two strongest names right now.

Liberation Labs is the capacity bet. Capra Biosciences is the small but serious API manufacturing watch. Synonym, now Roebling, is relevant but has moved away from being a pure synthetic-biology company.

Culture Biosciences is ahead because it attacks the boring problem that keeps killing good synthetic-biology ideas: scale-up. In December 2025, it closed a Series C to expand Stratyx 250 and its AI-powered Console software. Earlier in 2025, Cytiva expanded its collaboration with Culture around cloud-connected bioreactor technology. That matters because Cytiva is one of the major bioprocessing players, so the partnership gives Culture a stronger industrial signal than a standalone funding round.

Pow.Bio is more aggressive on process economics. Its strongest recent proof is that it scaled continuous fermentation to 3,000 liters in under 10 weeks at a CMO it had not worked with before. Then, in December 2025, it partnered with Bühler to bring an integrated continuous precision-fermentation platform to market. Compared with Culture, Pow.Bio is less of a cloud bioprocessing platform and more of a cost-curve company. If continuous fermentation works reliably, it can change the economics of whole categories, not just make R&D cleaner.

Liberation Labs is different. It is not trying to win by having the cleverest strain or the smartest software. Instead, it is building fermentation capacity. In January 2025, it closed $50.5 million for large-scale precision-fermentation facilities, and in April 2025, NEOM Investment Fund made a strategic investment tied to a facility in Saudi Arabia. In today’s market, that positioning is important because many fermentation startups failed less from biology than from missing affordable, reliable production capacity.

Capra Biosciences is smaller, but we should not ignore it. Its $7.5 million BioMaP project agreement is focused on rapid manufacturing of biologically derived small-molecule APIs. That is narrower than Culture or Pow.Bio, but more concrete than many “future biomanufacturing platform” claims. If the market keeps caring about domestic medicine supply chains, Capra’s category becomes more valuable.

Synonym/Roebling is the least clean fit. It started with biomanufacturing infrastructure and techno-economic analysis, then shifted toward broader industrial infrastructure planning. That still helps synthetic biology, but it makes the company harder to rank beside Culture or Pow.Bio. Today, we would call it adjacent infrastructure, not a pure biomanufacturing leader.

Which cell-programming startups are turning biology into repeatable products?

Asimov and bit.bio are the strongest answers. Cellino and Eligo Bioscience are worth watching, but they sit in narrower or more adjacent lanes.

Asimov is probably the best overall synthetic-biology platform company right now. The reason is simple: its recent proof is dense. In January 2025, Novo Nordisk licensed its CHO Edge system. In March 2025, LOTTE Biologics partnered with Asimov for cell-line development and GMP scaling. In April 2025, Cytiva collaborated with Asimov on cell-line design and process development. In July 2025, Asimov announced FDA IND clearance and clinical dosing for a bispecific antibody produced using CHO Edge. Then in 2026, it added viral-vector manufacturing work with AGC Biologics and launched RNA Edge for AI optimization of RNA therapeutic candidates.

That is a very different profile from most synthetic-biology startups. Many companies have one good round, one good paper, or one famous partner. Asimov has repeated signals across pharma, CDMOs, tools, clinical manufacturing, and RNA. We can be pretty confident now that it is not just a beautiful platform story.

bit.bio is the more productized cell-programming company. In January 2026, it raised $50 million in Series C funding after reported 2024 sales of £6.9 million and 172.91% annual sales growth over three years. That sales number matters because private synbio companies often hide behind “traction” without showing revenue. bit.bio is selling defined human cells into drug discovery and biomedical research, which makes it easier to compare with real customer demand.

The hierarchy between Asimov and bit.bio is clear. Asimov looks more strategic because it plugs into therapeutic manufacturing and high-value biologics workflows. bit.bio looks more commercial today because it has visible product revenue. Both are strong, but they answer different questions: Asimov is a platform embedded in the manufacturing stack; bit.bio is a programmable-cell supplier already selling into labs.

Cellino belongs near this category, but not at the center. Its ARPA-H support and reported FDA Advanced Manufacturing Technology designation point to automated stem-cell manufacturing. That could become critical for scalable cell therapies, but it is more manufacturing automation than classic synthetic biology.

Eligo Bioscience is more niche and more speculative, but technically interesting. It is trying to edit the microbiome in place, including skin microbiome applications. Its recent French government grant, Nature-linked work, patents, and expanded Series B make it credible. Still, compared with Asimov and bit.bio, Eligo has less public commercial proof.

If you want more recent data on this point, please see our latest synthetic biology market report.

Which DNA-writing startups control the picks-and-shovels layer?

Ansa Biotechnologies is the current standout. Constructive Bio is the bolder synthetic-genome bet. Molecular Assemblies and Camena Bioscience remain credible, but their recent public momentum is weaker.

Ansa is ahead because its October 2025 $54.4 million Series B came with a very practical promise: an “on-time or free” synthetic DNA service. That sounds almost too simple, but in DNA synthesis, reliability is the product. Customers do not only want theoretical sequence length but the actual DNA to arrive when experiments are scheduled. Compared with older DNA-synthesis startups, Ansa is making the market judge it on delivery performance, not only technology architecture.

Constructive Bio is more ambitious than Ansa, but also less straightforward commercially. It is building organisms with recoded genomes so they can make molecules natural biology cannot easily produce. In October 2025, it partnered with the Ellison Institute of Technology’s Generative Biology Institute, with upfront licensing, shared commercial rights, and royalties. That is a strong signal because someone paid for access to the platform. Still, compared with Ansa, Constructive Bio is further from becoming a simple horizontal supplier.

Molecular Assemblies remains important because enzymatic DNA synthesis could eventually replace or complement traditional chemical synthesis. The issue is freshness. Its financing and platform signals are real, but Ansa currently has the more recent market-facing proof.

Camena Bioscience has a good technical position in long and complex gene synthesis, yet its strongest public financing signal is older. It belongs in the credible group, but not in the top two today.

Which synthetic-biology startups are actually selling useful molecules?

Antheia is the strongest current answer. Solugen is still the established industrial-biology leader, while Capra Biosciences and Mango Materials sit in the emerging and watchlist buckets.

Antheia has become one of the clearest “synthetic biology meets real supply-chain pain” companies. In June 2025, it raised $56 million to commercialize thebaine, its first product, and expand a pipeline of more than 70 biosynthetic pharmaceutical ingredients across seven therapeutic areas. That is already meaningful. What makes it stronger is the context: essential medicines and pharmaceutical ingredients have obvious supply-chain fragility, so the customer problem is easier to understand than in many consumer synbio markets.

Compared with Solugen, Antheia is less mature but hotter right now. Solugen has raised far more historically and remains one of the best-known enzymatic chemical manufacturing companies. Its ADM partnership gave it serious industrial credibility. But the freshest startup momentum is stronger at Antheia because its 2025 financing is tied to a named first commercial product and a large API pipeline.

Capra Biosciences is the smaller emerging version of this thesis. Its BioMaP-backed project around biologically derived small-molecule APIs is not as large as Antheia’s raise, but the logic is similar: use biology to make critical molecules with better supply-chain resilience. Capra is not a leader yet, but it is worth watching because the problem it targets is becoming more important.

Mango Materials is interesting, but we should be stricter here. Turning methane from waste streams into biodegradable PHA is a strong technical and environmental story. Still, without a very fresh financing, customer, or scale-up signal, it does not belong in the same tier as Antheia or Solugen.

Today, Antheia is the one we would highlight first. Solugen keeps its established-leader status. Capra is the emerging API manufacturing name. Mango needs more proof before we call it hot.

If you want more recent data on this point, please see our latest synthetic biology market report.

Which agriculture synbio startups still look alive after the agtech reset?

Inari, Pairwise, Pivot Bio, and Hexagon Bio are the serious names. Andes is promising, but the current proof is thinner.

Inari is the top agriculture synthetic-biology startup by capital strength. In January 2025, it raised $144 million at a reported $2.17 billion valuation, up from about $1.65 billion one year earlier. That 32% valuation step-up matters because agtech has been a difficult funding market. Investors did not just keep Inari alive: they actually marked it up. That makes Inari stand out from many crop-biology startups that still have good science but weaker financing momentum.

Pairwise looks like the sharper partnership story. Its September 2024 $40 million Series C came with a five-year joint venture with Corteva for climate-resilient corn and soy. Compared with Inari, Pairwise has less capital behind it. But its Corteva relationship gives it a direct route into crops where distribution and regulatory know-how matter as much as gene-editing talent.

Pivot Bio is the incumbent in microbial nitrogen. It has raised around $600 million historically and had one of the rare acreage-scale adoption stories in synbio agriculture, replacing synthetic nitrogen on more than 1 million acres back in 2021. The catch is freshness. Pivot Bio remains important, but its most impressive public scale signal is older than Inari’s financing and Pairwise’s Corteva deal. We should treat it as a proven category leader, not the hottest current mover.

Hexagon Bio is the new surprise. In December 2025, Corteva and Hexagon announced a multi-million-dollar joint venture to develop nature-inspired crop protection products. This is interesting because Hexagon came from natural-product discovery with more of a pharma flavor. Corteva pulling it into crop protection suggests that agriculture is borrowing discovery tools from biotech.

Andes is worth tracking because soil carbon and microbial crop technologies remain strategically important. It has raised about $38 million, including a $15 million Series A in 2023, and has investors like Leaps by Bayer. But compared with Inari, Pairwise, and Hexagon, we do not yet see a recent commercial or strategic signal strong enough to put it in the same tier.

So, Inari leads on capital and valuation, Pairwise leads on crop-platform partnership, Pivot Bio leads on historical acreage proof, and Hexagon Bio is the freshest cross-over entrant.

Which gene-editing startups have pharma partners voting with real money?

Mammoth Biosciences, Scribe Therapeutics, Tessera Therapeutics, Profluent, and Eligo Bioscience stand out. Mammoth is the strongest current answer because its newest deal is both fresh and large.

Mammoth’s June 2026 Bayer deal is one of the freshest signals in the whole market. Bayer is paying $40 million upfront for a collaboration around up to five in vivo liver-targeted CRISPR drugs, with potential value around $1 billion. Mammoth already had a Regeneron collaboration in 2024, including $100 million upfront and up to $370 million per target in milestones. That gives Mammoth a cleaner pharma-validation profile than almost any private CRISPR platform company right now.

Scribe Therapeutics is close behind. In January 2025, it hit a success milestone in its Sanofi collaboration for in vivo CRISPR therapeutics. Public deal terms across Sanofi and Lilly-related programs point to more than $1 billion in possible milestones.

We should not confuse milestones with guaranteed revenue, but the number of major pharma partners tells us something real: buyers still want engineered CRISPR systems if delivery and specificity can improve.

Tessera Therapeutics is the most ambitious of the group. Its gene-writing platform is trying to go beyond classic cutting-and-repair editing. In December 2025, Regeneron put $150 million behind Tessera’s alpha-1 antitrypsin deficiency program. That makes Tessera hard to dismiss, even if the technical and clinical risk is high.

Profluent returns here because AI-designed genome editors are one of the most interesting bridges between synthetic biology and gene editing.

As seen above, Profluent has both a large recent financing and usage around OpenCRISPR-1. It is not yet as pharma-deal-heavy as Mammoth or Scribe, but it may be building a different kind of advantage: faster editor discovery.

Eligo is the niche bet. It is not competing head-on with Mammoth or Scribe for broad in vivo liver editing. Its target is microbiome editing, including skin applications. That makes it less proven commercially, but more differentiated scientifically.

If we force a hierarchy, Mammoth leads on current pharma validation, Scribe is the steady deal-backed CRISPR platform, Tessera is the high-risk gene-writing moonshot, Profluent is the AI-editor challenger, and Eligo is the microbiome-editing specialist.

If you want more recent data on this point, please see our latest synthetic biology market report.

Which precision-fermentation startups still look hot?

Liberation Labs, Pow.Bio, and StrainX Bioworks are the names to watch.

The key point is that the exciting part of precision fermentation has moved away from consumer food brands and toward capacity, cost, and process control.

Liberation Labs is the strongest capacity play. In January 2025, it closed $50.5 million for large-scale precision-fermentation facilities. In April 2025, NEOM Investment Fund added a strategic investment tied to a Saudi facility. That is important because fermentation startups often fail at the same wall: they can make the product, but not at the volume or cost customers need. Liberation Labs is attacking that wall directly.

Pow.Bio is the stronger process bet. As pointed out above, its 3,000-liter continuous fermentation scale-up and Bühler partnership make it one of the few startups with recent proof around fermentation economics. Compared with Liberation Labs, it is not mainly a capacity owner. It is trying to make the process itself more productive.

StrainX Bioworks is the emerging name here. In May 2026, the India-based synthetic biology and precision-fermentation startup raised $13 million in Series A funding after operating in stealth for two years. The round is much smaller than the U.S. infrastructure rounds, so we should not over-rank it. But as a fresh market signal, it matters: precision fermentation is now producing credible new entrants outside the usual U.S.-Europe cluster.

Which biomaterials startups have real proof, not just nice samples?

Sqim is the freshest standout. MycoWorks, Modern Meadow, and Mango Materials remain relevant, but this category still has too many companies with old hype and not enough current proof.

Sqim has the clearest recent signal because Bottega Veneta released a limited collection of small leather goods using Ephea, Sqim’s mycelium-based material, in June 2026. That is a strong brand-validation moment. Luxury is not huge volume, but it is a brutal quality filter. If a material works inside Bottega Veneta’s intrecciato design language, it has passed a higher bar than a trade-show sample.

MycoWorks still has the bigger historical reputation. It raised about $225 million and helped define the mycelium-leather category. But its recent story looks less clean. The company is now under the stewardship of DFX Corporation, which sounds more like restructuring than breakout momentum. We should keep it in the established bucket, not the hot bucket.

Modern Meadow also remains credible, especially given its long work in biofabricated materials. The issue is similar: the strongest proof is not fresh enough. In a category where many materials startups looked promising and then struggled with scale, old credibility is not enough.

Mango Materials has the most interesting environmental angle because it turns methane from waste streams into biodegradable PHA. But compared with Sqim, the current customer signal is weaker. We need fresher proof before moving it up.

Which synthetic-biology moonshots are too big to ignore?

Colossal Biosciences is the obvious one. Constructive Bio and Latent Labs are the more technical moonshots.

Colossal is impossible to ignore because it has the largest private-company signal in synthetic biology. In January 2025, it raised $200 million at a $10.2 billion valuation, bringing total funding to $435 million. In April 2025, it announced genetically engineered wolves with dire-wolf-like traits, which created huge public attention and a lot of scientific pushback.

We should be very precise about Colossal. The company is not proof that de-extinction is commercially solved. Its own chief scientist later clarified that the animals are gray wolves with edited genes, not literal resurrected dire wolves.

But Colossal does prove something else: conservation genetics, embryo engineering, and high-profile synthetic biology can attract decacorn-scale capital. No other private synbio company has that kind of cultural and financial gravity.

Constructive Bio is the cleaner science moonshot. Instead of editing a few traits into an animal, it is trying to rewrite genetic codes so organisms can produce molecules natural biology cannot. Its 2025 Ellison Institute partnership makes that ambition more credible because it creates a translational path beyond academic imagination.

Latent Labs is the AI moonshot. Its recent Latent-X and Latent-Y work points toward a world where protein and antibody design becomes less like screening and more like guided generation. That is still early, but the technical claims are specific enough that we can judge them.

So we believe Colossal wins the spectacle and valuation race. Constructive Bio wins the genetic-code ambition race. Latent Labs wins the “AI could actually change discovery workflows” race.

If you want more recent data on this point, please see our latest synthetic biology market report.

Which startups keep showing up when we aggregate all the evidence?

Asimov, Antheia, Profluent, Latent Labs, Culture Biosciences, Ansa Biotechnologies, Inari, Mammoth Biosciences, bit.bio, Pow.Bio, and Colossal Biosciences are the strongest overall group.

Asimov keeps coming back because it has the rarest pattern: repeated partner and product signals across therapeutic manufacturing, cell-line development, viral vectors, and RNA.

Antheia stands out because it connects synthetic biology to essential medicine supply, where the customer pain is obvious and urgent. Profluent and Latent Labs are the AI-biology names where the recent signals are strong enough to be taken seriously now, not in some vague future.

Culture Biosciences and Pow.Bio matter because synthetic biology’s limiting factor is often manufacturing. Ansa matters because DNA synthesis is one of the input layers everyone else depends on. Inari matters because agriculture is hard, slow, and capital-intensive, yet it still raised at a higher valuation in 2025. Mammoth matters because pharma is backing its CRISPR systems with real deal economics. bit.bio matters because it has visible sales, not just platform language. Colossal matters because even after we discount the hype, the valuation signal is too large to ignore.

The interesting thing is that these companies do not all look alike.

Some are infrastructure companies. Some are therapeutic platforms. Some sell cells or DNA. Some make molecules. Some sell a moonshot.

But they all share one feature: recent external validation that is hard to fake.

So, who are the top synthetic biology startups right now?

The strongest synthetic biology startups right now are Asimov, Antheia, Profluent, Latent Labs, Culture Biosciences, Ansa Biotechnologies, Inari, Mammoth Biosciences, bit.bio, Pow.Bio, and Colossal Biosciences.

If we had to pick the most complete company, it would be Asimov.

It has the broadest evidence stack: pharma partners, CDMO links, clinical manufacturing proof, and new product expansion. If we had to pick the hottest emerging AI-biology companies, it would be Profluent and Latent Labs. Profluent has the financing and early usage; Latent Labs has the sharper recent technical benchmarks. If we had to pick the most strategically useful biomanufacturing names, Culture Biosciences and Pow.Bio are ahead because they address the scale-up and cost problems everyone else runs into.

Antheia is the best current commercial-molecule story because it is not selling a vague “bio-based future.”

It is going after essential pharmaceutical ingredients, with named products and a large pipeline. Ansa is the best DNA-writing infrastructure name because it is competing on delivery reliability. Inari is the top ag-biology startup because the funding and valuation step-up are hard to ignore in a weak agtech market. Mammoth is the strongest private CRISPR platform by recent pharma-deal validation. bit.bio is the clearest programmable-cell product company. Colossal is the biggest moonshot, though it needs the most careful wording because the science and the branding do not always line up cleanly.

So, to conclude, synthetic biology is not dying, but the easy storytelling phase is over.

The companies that look strongest today are the ones with recent proof from customers, pharma partners, strategic investors, clinical or manufacturing progress, or technical benchmarks that can be compared.

That is why this top group feels more defensible than a simple fame-based ranking.

Category	Startups selected and why
AI biology and programmable proteins	Profluent and Latent Labs lead. Profluent is ahead on recent financing and usage; Latent Labs is ahead on fresh technical benchmarks. Cradle is the practical workflow company, EvolutionaryScale remains the famous model leader, and Basecamp is the biodiversity-data wildcard.
Biomanufacturing infrastructure	Culture Biosciences and Pow.Bio lead. Culture is strongest on cloud-connected bioprocess infrastructure; Pow.Bio is strongest on continuous-fermentation economics. Liberation Labs leads on capacity, Capra is the emerging API manufacturing watch, and Synonym/Roebling is now more adjacent infrastructure.
Cell programming	Asimov and bit.bio lead. Asimov has the densest partner and product signal stack; bit.bio has visible sales and new scale-up funding. Cellino is adjacent manufacturing automation, and Eligo is the microbiome-editing specialist.
DNA synthesis and genome writing	Ansa leads on DNA-synthesis execution because of its 2025 Series B and delivery guarantee. Constructive Bio leads on synthetic-genome ambition. Molecular Assemblies and Camena are credible but need fresher public acceleration.
Commercial molecules and APIs	Antheia leads because its 2025 financing is tied to thebaine commercialization and a 70-plus ingredient pipeline. Solugen remains the established industrial-biology leader. Capra is the emerging domestic API manufacturing name, while Mango Materials needs fresher commercial proof.
Agriculture and crop biology	Inari leads on capital and valuation, Pairwise leads on Corteva-backed crop platform work, Pivot Bio leads on historical microbial-nitrogen acreage proof, and Hexagon Bio is the freshest cross-over entrant through Corteva. Andes is promising but less proven right now.
Gene editing and gene writing	Mammoth leads on current pharma validation because of Bayer and Regeneron. Scribe is the steady deal-backed CRISPR platform, Tessera is the high-risk gene-writing bet, Profluent is the AI-editor challenger, and Eligo is the microbiome-editing specialist.
Precision fermentation	Liberation Labs, Pow.Bio, and StrainX Bioworks lead. Liberation Labs is the capacity play, Pow.Bio is the process-economics play, and StrainX is the fresh emerging entrant outside the usual U.S.-Europe cluster.
Biomaterials	Sqim is the fresh standout because of Bottega Veneta’s Ephea launch. MycoWorks and Modern Meadow remain known but less clearly hot. Mango Materials has a strong methane-to-PHA angle, but current proof is thinner.
Moonshots	Colossal, Constructive Bio, and Latent Labs lead. Colossal wins on valuation and attention, Constructive Bio wins on genetic-code rewriting ambition, and Latent Labs wins on AI-driven drug-design ambition.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.